Linked Life Data

19037879

Source:http://linkedlifedata.com/resource/pubmed/id/19037879

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2009-2-9
pubmed:abstractText
COPD (chronic obstructive pulmonary disease) is a significant health concern as the fourth leading cause of morbidity and mortality in the U.S.A. Although the prevalence of PH (pulmonary hypertension) in COPD is unknown, its presence is a risk factor for mortality. In this comment, we consider the role of PH in COPD and its pathophysiology, with reference to ET-1 (endothelin-1) and cigarette smoke, as well as exercise and nocturnal hypoxia. We also explore potential mechanisms for the observed improvement in exercise tolerance following 6 months of pravastatin treatment in COPD patients with PH as reported by Lee and co-workers in the present issue of Clinical Science, including possible effects upon ET-1 and Rho kinase, or antioxidant effects, which may be particularly relevant in this group of mainly current smokers.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1470-8736
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
116
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
493-5
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Role of pravastatin in pulmonary hypertension in chronic obstructive pulmonary disease.
pubmed:affiliation
Department of Pulmonary Hypertension, Royal Brompton Hospital. Sydney St, London SW3 6NP, UK.
pubmed:publicationType
Journal Article, Comment